Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xilio Therapeutics
Biotech
Gilead pays $43.5M for Xilio's early-phase IL-12 prospect
Gilead is bucking the trend in IL-12, entering the space after seeing rivals such as AstraZeneca and Bristol Myers Squibb retreat from the cytokine.
Nick Paul Taylor
Mar 28, 2024 8:08am
Illumina nets new CEO—Chutes & Ladders
Sep 8, 2023 9:30am
Drugs up for sale, on the shelf in biotech pipeline clear-outs
Nov 9, 2022 9:40am
Xilio inks Merck deal to run checkpoint inhibitor combo trial
May 25, 2021 8:55am
Xilio raises $95M to take twists on Yervoy and IL-2 into clinic
Feb 24, 2021 8:00am
Akrevia no more, Xilio Therapeutics bags $101M for I-O programs
Mar 2, 2020 7:00am
